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ABSTRACT  
Objective: Statins have several pleiotropic effects, but the literature regarding the possible 
relationship between statins use and outcomes in knee osteoarthritis (OA) is limited. We 
investigated whether statins use is associated with lower risk of radiographic (ROA), 
radiographic symptomatic knee OA (SxOA) and pain in North American people.  
Methods: A total of 4,448 community-dwelling adults from the Osteoarthritis Initiative were 
followed-up for 4 years. Statins use (including the time from baseline and the type) was 
defined through self-report information and confirmed by a trained interviewer. Knee OA 
outcomes included incident (1) ROA, (2) SxOA, as the new onset of a combination of a 
painful knee and ROA, (3) knee pain worsening, i.e. a Western Ontario and McMaster 
Universities Osteoarthritis Index difference between baseline and each annual exam ≥14%.  
Results: At baseline, 1,127 participants (=25.3%) used statins. Based on a multivariable 
Poisson regression analysis with robust variance estimators, any statins use was not 
associated with lower risk of pain worsening (relative risk, RR=0.97; 95%CI, confidence 
intervals: 0.93-1.02), incident ROA or SxOA. However, statins use > 5 years (RR=0.91; 
95%CI: 0.83-0.997) and atorvastatin use (RR=0.95; 95%CI: 0.91-0.996) were associated with 
a reduced risk of developing pain, whilst rosuvastatin to a higher risk (RR=1.18; 95%CI: 
1.12-1.24). The adjustment for the propensity score confirmed these findings.  
Conclusion: The effect of statins use on knee OA outcomes remains unclear, although in our 
study those using statins for over five years and those using atorvastatin reported a significant 
lower risk of developing knee pain.  
 
Keywords: osteoarthritis; statins; aged; Osteoarthritis Initiative; pain; knee osteoarthritis. 
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SIGNIFICANCE AND INNOVATIONS 
 The effect of statins on knee osteoarthritis outcomes are still limited.  
  In our study, we found that statins were not associated with a reduced risk of future pain 
in people with/at risk of knee osteoarthritis  
 People using statins for over five years and those using atorvastatin reported a significant 
lower risk of future pain due to knee osteoarthritis.  
 No effect was found for incident symptomatic knee osteoarthritis or for radiographic 
forms of knee osteoarthritis.  
 
INTRODUCTION 
Statins are competitive inhibitors of hydroxymethyl-glutaryl-coenzyme reductase, an enzyme 
involved in the cholesterol biosynthesis.(1) These medications are commonly used for 
treating hypercholesterolemia.(1, 2) In addition to their primary indication, there is growing 
evidence that statins also have important pleiotropic effects, such as the improvement of 
endothelial dysfunction, stabilization of atherosclerotic plaques, increased nitric oxide 
bioavailability, antioxidant properties, and inhibition of inflammatory responses.(1, 3)  
 
Inflammation plays a pivotal role in the development and progression of knee osteoarthritis 
(OA)(4, 5), the most common form of osteoarthritis worldwide.(6) It was reported that statins 
have multiple effects on inflammation at cellular and extra-cellular level, including reduction 
in inflammatory cytokines and T cell activation.(7) Given that many of these systems are 
influential on OA, it is possible that statins may have a role in altering the course of the 
progression of knee OA and its symptomatology, which may be counteracted by the well-
known muscle ache, developed under long-term statins use. In fact, statin use has a well-
established side effect of muscle ache and statins exacerbate declines in muscle performance 
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and lead to increase in falls risk, that are associated with aging, without a significant decrease 
in muscle mass.(8) 
 
The literature regarding the effect of statins on OA outcomes (such as progression and pain) 
is, however, limited to a few studies. In the Rotterdam study, 2,921 older participants were 
followed-up over 6.5 years. In this research, statins use was associated with more than a 50% 
reduction in overall progression of knee OA.(9) However, in another large cohort with a 
follow-up of 8 years, older women taking statins at baseline were found to be at an increased 
risk of hip OA(10), whilst the authors did not report any data regarding knee OA. Although 
these studies have advanced our knowledge regarding the effect of statins use in OA, some 
limitations and unanswered questions persist.  First, only a radiographical diagnosis of OA 
was used. Therefore, the effect of statins on pain due to OA is not known, but could be of 
clinical importance.(11) Second, the number of covariates used for adjustments was generally 
low introducing possible residual confounding in these findings. Finally, these studies did not 
use propensity score matching, a method that seems the most appropriate in comparing the 
effect of medications in observational studies.(12)  
 
Given this background, we aimed to investigate whether statins use is associated with lower 
risk of radiographic (ROA), radiographic symptomatic knee OA (SxOA) and pain worsening 
due to knee OA, in a large cohort of North American people followed-up for 4 years.  
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MATERIALS AND METHODS 
Data source and subjects 
Data were obtained from the Osteoarthritis Initiative (OAI) database 
(http://www.oai.ucsf.edu/). Within the OAI, participants were recruited across four clinical 
sites in the United States of America (Baltimore, MD; Pittsburgh, PA; Pawtucket, RI; and 
Columbus, OH) between February 2004 and May 2006. In this project, people were included 
if they: (1) had knee OA with knee pain for a 30-day period in the past 12 months or (2) were 
at high risk of developing knee OA (e.g. obese/overweight, familiarity for knee OA).(13) The 
data were collected during the baseline and in screening evaluations and in subsequent 
evaluations until four years of follow-up. All participants provided written informed consent. 
The OAI study was given full ethics approval by the institutional review board of the OAI 
Coordinating Center, at the University of California in San Francisco. 
 
Use of statins (exposure) 
Statins use was assessed at baseline using a specific questionnaire investigating the name of 
the prescription medicine, duration of use, and formulation code in the 30 days before the 
interview. Trained interviewers checked the medications used by each participant. The statins 
included in the interview were: rosuvastatin, atorvastatin, lovastatin, simvastatin, pravastatin, 
fluvastatin. The duration of use of these medications were recorded in the OAI at baseline 
evaluation and categorized as: < 1 month, between 1 month and < 1 year, between 1 and < 3 
years, between 3 and < 5 years and more than 5 years. Statins use during follow-up was also 
recorded and used in the analysis.  
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Assessment of knee OA outcomes 
At baseline and during follow-up examinations, individuals had full knee assessments which 
included both a clinical and radiographic examination. People with knee replacement at 
baseline were removed from all the analyses. A fixed flexion posterior–anterior radiograph, 
which was read centrally for Kellgren and Lawrence (KL) grade, was made for all the 
participants. In addition, participants were asked regarding knee pain, the following question: 
‘During the past 30 days, have you had pain, aching, or stiffness in your right/left knee on 
most days?’. Knee pain was also assessed using the WOMAC (Western Ontario and 
McMaster Universities Osteoarthritis Index) pain subscale. This scale ranges from 0 (absence 
of pain) to 20 (highest pain) points.    
 
The knee outcomes of interest for this study included: incident (1) ROA (radiographical 
osteoarthritis), if a knee developed a KL grade ≥2 at follow-up and was not present at 
baseline, (2) SxOA (symptomatic osteoarthritis), defined as new onset of a combination of 
painful knee plus the presence of ROA present at the same side and (3) knee pain worsening, 
i.e.  WOMAC pain score difference of a knee between baseline and each annual exam ≥14% 
or the onset of pain during follow-up in people having zero at baseline in accordance with 
previous research.(14, 15) The assessment of these knee OA outcomes was made, other than 
at baseline, at V01 (12 months), V03 (24 months), V05 (36 months), and V06 (48 months). 
 
Covariates 
Ten covariates at baseline (other than age and sex) were identified as potential confounding 
factors based on previous literature.(16) These included: race (whites vs. others); educational 
attainment (college or higher vs. others); body mass index (BMI); yearly income (< vs > 
$50,000 or missing data); depressive symptoms assessed using the Center for Epidemiologic 
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Studies Depression Scale (CES-D)(17); smoking habits; physical activity evaluated using the 
total score for the Physical Activity Scale for the Elderly scale (PASE)(18); Charlson 
Comorbidity Index score(19), a validated general health measure of self-reported 
comorbidities; the number of medications used; the maximum knee extension strength 
(between left and right lower limb), after three trials for each side. Statins use during follow-
up was also recorded and used as covariate. 
Statistical analyses 
Data on continuous variables were normally distributed according to the Kolmogorov-
Smirnov test. Data were presented as means and standard deviation values (SD) for 
quantitative measures, and percentages for all categorical variables by the use or not of statins 
at baseline. P values were calculated using an independent T test for continuous variables and 
a chi-square test for categorical parameters.   
 
To assess the relationship between statins use and the outcomes (ROA, SxOA, pain 
worsening), a multivariable Poisson regression analysis with robust variance estimators was 
applied, since a survival analysis was not possible due to lack of information on the precise 
date of event. The fully adjusted model included age; sex; race (whites vs. others); education 
(degree vs. others); body mass index (as continuous); yearly income (categorized as > or < 
50,000$ and missing data); CES-D: Center for Epidemiologic Studies Depression Scale; 
smoking habits (current and previous vs. others); Physical Activity Scale for Elderly score (as 
continuous); Charlson co-morbidity index; number of medications used; use of statins during 
follow-up period; maximum knee extension. Multi-collinearity among covariates was 
assessed through variance inflation factor (VIF)(20), taking a cut-off of 2 as the criterion for 
exclusion. No covariates were excluded using this criterion. Adjusted relative risks (RRs) and 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
95% confidence intervals (CI) were calculated to estimate the strength of the associations 
between statins use and incident knee OA outcomes.  
 
We ran several sensitivity analyses assessing the association between statins use and incident 
knee OA outcomes. First, we used the propensity score that is a statistical matching technique 
that attempts to estimate the effect of a treatment by accounting for the covariates that predict 
receiving the treatment.(12) The propensity score, divided into quintiles, was estimated by 
using a logistic regression model regressing baseline statins use on the above-mentioned 
covariates. Second, we ran an analysis using the periods of use of statins from baseline 
evaluation (as defined before) as exposure. Finally, we used the type of statin (rosuvastatin, 
atorvastatin, lovastatin, simvastatin, pravastatin, fluvastatin) as the exposure. In all these 
elaborations, people not using statins were taken as the reference group.  
 
A p<0.05 was deemed statistically significant.  All analyses were performed using SPSS
®
 
software version 17.0 for Windows (SPSS Inc., Chicago, Illinois) and STATA
®
 software 
version 14.1 (Stata Corp LP, College station, Texas). 
 
RESULTS 
Sample selection 
The OAI dataset initially included a total of 4,796 individuals. We excluded 63 participants 
with a total knee replacement at baseline (since they cannot develop any of the outcomes of 
interest) and a further 285 with no data regarding outcomes of interest during follow-up, 
obtaining a final sample of 4,448 people.    
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Descriptive characteristics  
The cohort consisted of 2,584 females (58.1%) and 1,864 males (41.9%), with a mean age of 
61.1 years (±9.2 years; range: 45-79 years). Of the entire cohort, 1,127 participants (=25.3% 
of population) used statins at baseline, mainly for a period between one month and one year 
(=10.4%) from baseline. The most frequent statin use reported was atorvastatin, used by 603 
people (=13.6%). At baseline, 2,512 had knee ROA (=56.5% of baseline population) and, of 
them, 1,082 had knee SxOA (=24.3%).  
 
Table 1 shows the baseline characteristics by statins use or not. Compared to the 3,321 
participants not using statins, people using statins were older, and were more likely to be 
males, sedentary, whites, and smokers. People using statins were more obese and had a higher 
number of co-morbidities, using a higher number of medications. Finally, people using statins 
had a significant higher prevalence of knee ROA (59.4 vs. 55.5, p=0.02) and reported a 
higher level of WOMAC pain at both knees (p=0.001 for right knee and =0.002 at left knee). 
However, no difference emerged for the prevalence of knee SxOA (Table 1).  
 
Statins use and incident knee osteoarthritis outcomes 
During the four years of follow-up, 431 people developed ROA. Of them, 201 had a SxOA. 
Pain worsening was observed in 3,678 subjects.  
As shown in Table 2, during a mean follow-up period of 4 years, after adjusting for potential 
confounders at baseline and statins use during follow-up, participants using any statins did 
not report significant lower risk of pain worsening (RR=0.97; 95%CI: 0.93-1.02; p=0.23) and 
no differences emerged for incident knee ROA (RR=1.31; 95%CI: 0.83-2.09; p=0.25) or for 
knee SxOA (RR=0.97; 95%CI: 0.87-1.09; p=0.63) either. The adjustment for the propensity 
score substantially confirmed these findings.  
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In Table 3, we assessed the association between period of use of statins and incident knee 
OA outcomes. Only the use of a period of more than 5 years was associated with a decrease 
in pain during the follow-up period (RR=0.91; 95%CI: 0.83-0.997; p=0.04 in fully-adjusted 
model; RR=0.90; 95%CI: 0.82-0.993; p=0.03 after adjusting for the propensity-score). We 
did not observe any significant associations between statins use and radiographic or 
symptomatic knee OA for the other periods of use included (Table 2).  
 
Regarding individual agents, atorvastatin was the only statin associated with a lower risk of 
pain worsening (RR=0.95; 95%CI: 0.91-0.996; p=0.03), whilst rosuvastatin was associated 
with a higher risk of pain worsening (RR=1.18; 9%%CI: 1.12-1.24; p<0.0001), as reported in 
Figure 1. No statins were associated with a significant effect on incident ROA or SxOA 
(details not shown, available on request from corresponding author).  
 
DISCUSSION 
In this large longitudinal study over a 4-year follow-up period, our results suggest that statins 
use is not associated with a lower risk of pain worsening, symptomatic and radiographic knee 
OA when the time of statins use and the type of statin was not taken into account. However, 
using statins for more than 5 years from baseline and atorvastatin use were associated with 
reduced pain worsening as well as rosuvastatin to a higher risk.  
 
It was reported that statins may have several positive effects on knee OA outcomes due to 
several reasons. First, the anti-inflammatory effect can contribute to the reduction in pain 
worsening during follow-up that we observed. However, the effect of statins on 
musculoskeletal pain is probably contradictory and can overcome the anti-inflammatory 
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properties of these medications. It is traditionally known that statins might lead to muscular 
pain as side effect(21), but a large randomized controlled trial (RCT) in people affected by 
rheumatoid arthritis reported a significant reduction of atorvastatin on pain, mainly due to a 
reduction in inflammatory parameters.(22) The association between statins and decrease in 
pain has been confirmed in some other observational studies.(23) There is however more 
limited data regarding OA. In a longitudinal study, among 16,609 participants with previous 
cardiovascular disease followed-up for 10 years, higher statin dose and larger statin dose 
increments were associated with a reduction in clinically defined OA outcome.(24) 
Unfortunately, the diagnosis of knee OA in this study was made through administrative data, 
limiting their reliability. (24) Therefore, future studies (particularly RCTs) are needed to 
understand if statins use can really decrease pain in people affected by knee OA. Second, 
statins may positively affect subchondral bone, another part usually damaged in knee 
OA.(25) Damaged subchondral bone in OA may result in vascular disease (particularly of 
small vessels), with localized vascular hypertension and ischemia that can further worsen 
progression.(26) Since statins cause vasodilatation and have anti-atherosclerotic effect, it is 
likely that these properties balance the negative effect on subchondral bone.(7) However, 
subchondral bone is better visualized through magnetic resonance imaging and therefore, we 
were unable to confirm the possible role of statins on this structure in our study.  
 
Another interesting finding of our research is that statins did not decrease the incidence of 
symptomatic and radiographic knee OA, which is in contrast to earlier cohort studies.(9, 24) 
We can hypothesize that some methodological aspects can influence these results. For 
example, the OAI includes only people with knee OA or at high risk of this condition. 
Furthermore, the diagnostic criteria used for the definition of symptomatic and radiographic 
knee OA, and the covariates used for adjustment in the analyses differed between studies. 
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Due to the importance of these outcomes, future studies are needed to better understand if 
statins are able to modify the natural history of knee OA.  
 
Finally, we found that statins use for more than 5 years was associated with lower risk of pain 
worsening. Overall, our research confirmed previous findings coming from large RCTs on 
cardiovascular disease and hypercholesterolemia, indicating that a benefit of statins remains 
more than 5 years and linearly increases with the duration of use.(27) Similarly, we found 
that people taking atorvastatin at baseline had a significant decreased risk in pain worsening 
of about 5%. Atorvastatin is a lipophilic statin(28) and it is known that, in in vitro models, 
lipophilic statins can block cartilage collagen breakdown induced by proinflammatory 
cytokines and by downregulating key cartilage-degrading enzymes in bovine nasal 
cartilage.(29) These authors, however, found these interesting effects only on other two 
lipophilic statins (simvastatin and mevastatin) for which, on the contrary, we failed to find 
any significant association. Therefore, other research is needed to confirm/refute our findings 
and to understand if the effect of lovastatin on pain worsening is peculiar or not. At the same 
time, another potent statin (rosuvastatin) increased the risk of pain worsening due to knee OA 
suggesting that hydrophilic statins may lead to an increase in pain more frequently than 
lipophilic ones. However other studies are needed to confirm our findings.    
The strengths of our study are the long duration of follow-up, the several knee OA outcomes 
assessed, and the large sample size included. However, our finding should be interpreted with 
some limitations. First, the participants of the OAI are at high risk or they already had knee 
OA. Thus, our results are not generalizable to the general population. Second, the 
observational nature of our findings can introduce another bias in our results, although we 
tried to correct this limitation using analyses adjusted for potential confounders and for the 
propensity-score. Third, most of the people taking statins, reported an use between 1 month 
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and 1 year and, probably, this is a too short time for detecting a clinical effect. Fourth, given 
that the sample size for analyses with ROA as the outcome had a small sample size, we 
cannot discard the possibility that the statistical non-significance observed was due to lack of 
statistical power. Finally, the record of medications is self-reported (although confirmed by a 
trained interview) and the data regarding the duration of use can be subject to recall bias.  
 
In conclusion, our data suggest that, overall, any statin use was not associated with a lower 
risk of pain worsening, radiographic and symptomatic knee OA due to knee OA in this large 
cohort of North American people. However, people using statins for more than 5 years and 
those using atorvastatin reported beneficial effects on pain worsening, whilst people taking 
rosuvastatin reported an increased risk for pain worsening.  Therefore, future RCTs are 
needed to confirm/refute our observational findings.  
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FIGURE LEGEND 
 
Figure 1. Association between type of statins and pain worsening during follow-up, 
adjusted for the propensity score in quintiles.  
 
Legend: Data are reported as odds ratios with 95% confidence intervals (CIs), adjusted for 
the propensity score, taking people not using statins as reference.  
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Table 1. Characteristics of the participants classified according to their baseline use of 
statins. 
 
Statins users 
(n=1127) 
No statins 
users 
(n=3321) 
p-value 
General characteristics    
Age (years) 64.3 (8.4) 60.0 (9.2) <0.0001 
Males (%) 46.9 40.2 <0.0001 
PASE (points) 149 (75) 167 (84) <0.0001 
White race (%) 82.1 79.5 0.05 
Smoking (previous/current) (%) 51.3 45.3 0.001 
Graduate degree (%) 30.3 31.3 0.55 
Yearly income (> $50,000) (%) 57.8 60.1 0.34 
Knee extension (Nm) 356 (129) 356 (133) 0.93 
Medical conditions    
BMI (Kg/m
2
) 29.5 (4.4) 28.3 (4.9) <0.0001 
CES-D (points) 6.3 (6.3) 6.6 (7.1) 0.20 
Charlson co-morbidity index (points) 0.6 (1.0) 0.3 (0.8) <0.0001 
Number of medications 4.5 (2.6) 2.4 (2.5) <0.0001 
Osteoarthritis items (at baseline)    
ROA (%) 59.4 55.5 0.02 
SxOA (%) 25.4 24.0 0.36 
WOMAC pain (right knee) 0.5 (0.5) 0.4 (0.5) 0.001 
WOMAC pain (left knee) 0.5 (0.5) 0.4 (0.5) 0.002 
Notes: The data are presented as means (with standard deviations) for continuous variables 
and percentages for categorical outcomes.  
Abbreviations: CES-D: Center for Epidemiologic Studies Depression Scale; PASE: Physical 
Activity Scale for the Elderly; BMI: body mass index; OA: osteoarthritis; WOMAC: Western 
Ontario and McMaster Universities Osteoarthritis Index. 
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Table 2. Association between baseline use of statins and incident knee osteoarthritis 
outcomes.  
 
Number of 
events/number 
of 
participants 
Full-adjusted 
model
1
 
(RR, 95%CI) 
p-value 
Propensity-
score model
2
 
(RR, 95%CI) 
p-value 
Pain 
worsening 
3,678/4,448 
(=82.7%) 
0.97 (0.93-1.02) 0.23 
0.97 (0.93-
1.02) 
0.24 
ROA 
431/1,936 
(=22.2%) 
1.31 (0.83-2.09) 0.25 
1.41 (0.86-
2.32) 
0.17 
SxOA 
201/3,364 
(=5.9%) 
0.97 (0.87-1.09) 0.63 
0.98 (0.88-
1.11) 
0.78 
 
Notes: 
All the data are presented as relative risk with their 95% confidence intervals. 
1 
Fully adjusted model included as covariates: age (as continuous); sex; race (whites vs. 
others); education (degree vs. others); body mass index (as continuous); yearly income 
(categorized as > or < 50,000$ and missing data); CES-D: Center for Epidemiologic Studies 
Depression Scale; smoking habits (current and previous vs. others); Physical Activity Scale 
for Elderly score (as continuous); Charlson co-morbidity index; number of medications used; 
use of statins during follow-up period; maximum knee extension. 
2
 Propensity score model 
included as covariate the propensity score divided into quintiles. 
Abbreviations:  CI: confidence intervals; RR: relative risk.  
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3. Association between duration of use of statins and incident knee osteoarthritis 
outcomes.  
 
Full-adjusted model
1
 
(RR, 95%CI) 
p-value 
Propensity-score 
model
2
 
(RR, 95%CI) 
p-value 
Pain worsening 
< 1 month  0.95 (0.84-1.08) 0.50 0.96 (0.85-1.09) 0.56 
1 month to 
1 year 
0.96 (0.91-1.02) 0.19 0.96 (0.91-1.02) 0.18 
1-3 years 1.05 (0.995-1.12) 0.07 1.06 (0.996-1.18) 0.07 
3-5 years 0.96 (0.89-1.04) 0.35 0.96 (0.89-1.05) 0.40 
>5 years 0.91 (0.83-0.997) 0.04 0.90 (0.82-0.993) 0.03 
Radiographic osteoarthritis  
< 1 month 0.85 (0.19-3.76) 0.83 0.92 (0.22-3.82) 0.91 
1 month to 
1 year 
1.32 (0.76-2.31) 0.32 1.45 (0.80-2.64) 0.22 
1-3 years 1.26 (0.63-2.49) 0.51 1.33 (0.68-2.66) 0.42 
3-5 years 1.31 (0.59-2.88) 0.51 1.32 (0.58-3.02) 0.50 
>5 years 1.49 (0.74-3.01) 0.26 1.64 (0.80-3.37) 0.18 
Symptomatic osteoarthritis  
< 1 month 0.88 (0.66-1.16) 0.35 1.10 (0.82-1.47) 0.53 
1 month to 
1 year 
0.96 (0.84-1.11) 0.61 0.97 (0.84-1.12) 0.66 
1-3 years 1.01 (0.85-1.20) 0.89 1.01 (0.85-1.21) 0.87 
3-5 years 1.02 (0.84-1.25) 0.85 1.03 (0.84-1.27) 0.75 
>5 years 0.93 (0.74-1.16) 0.50 0.90 (0.72-1.12) 0.35 
 
Notes: 
All the data are presented as relative risk with their 95% confidence intervals, taking those 
not using statins as reference.  
1 
Fully adjusted model included as covariates: age (as continuous); sex; race (whites vs. 
others); education (degree vs. others); body mass index (as continuous); yearly income 
(categorized as > or < 50,000$ and missing data); CES-D: Center for Epidemiologic Studies 
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Depression Scale; smoking habits (current and previous vs. others); Physical Activity Scale 
for Elderly score (as continuous); Charlson co-morbidity index; number of medications used; 
use of statins during follow-up period; maximum knee extension. 
2 
Propensity score model 
included as covariate the propensity score divided into quintiles.  
Abbreviations:  CI: confidence intervals; RR: odds relative risk.  
 
 
 
